Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Maxim Group Downgrades Aridis Pharmaceuticals to Hold

Maxim Group Downgrades Aridis Pharmaceuticals to Hold

Maxim Group analyst Jason McCarthy downgrades Aridis Pharmaceuticals (NASDAQ:ARDS) from Buy to Hold.

August 16, 2022

1 minute read

Maxim Group analyst Jason McCarthy downgrades Aridis Pharmaceuticals (NASDAQ:ARDS) from Buy to Hold.

$20M Bet On This Biotechnology Stock? Check Out These 3 Stocks Insiders Are Buying

October 18, 7:03 AM

Although U.S. stocks closed mixed on Tuesday, there were a few notable insider trades.

June 15, 5:01 PM

Analysts have provided the following ratings for CubeSmart (NYSE:CUBE) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…

October 20, 2:32 AM

After the Biden administration announced plans to buy oil to replenish the SPR, an analyst expressed surprised at the move.

March 27, 11:25 AM

Kala Pharmaceuticals Inc (NASDAQ:KALA) announced safety data from the first cohort of the CHASE Phase 2b clinical trial evaluating KPI-012, a…